Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

BAL-4079 enters phase III for severe chronic hand dermatitis

Nov. 2, 2004

New phase I/II study for CYT007-TNFQb for psoriasis

Oct. 28, 2004

Velac NDA accepted for filing

Oct. 27, 2004

Evoclin approved for acne vulgaris

Oct. 27, 2004

Phase II study for Levulan Kerastick in acne

Oct. 27, 2004

Enrollment completed in phase II actinic keratosis study of Polyphenon E

Oct. 26, 2004

Therapeutic benefits of topical bimosiamose in psoriasis vulgaris

Oct. 25, 2004

Alefacept approved in Canada for chronic plaque psoriasis

Oct. 22, 2004

Cambrex to market and distribute Orcel

Oct. 20, 2004

UCB Pharma to discontinue Olux, Luxiq copromotion

Oct. 19, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...